James L. Abbruzzese mainly investigates Internal medicine, Pancreatic cancer, Cancer research, Surgery and Cancer. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology and Oncology. James L. Abbruzzese has researched Oncology in several fields, including Metformin and Confidence interval.
James L. Abbruzzese combines subjects such as Immunology, Pancreatic disease, Pancreas and Adenocarcinoma with his study of Pancreatic cancer. His studies deal with areas such as Carcinogenesis, Transcription factor and Metastasis as well as Cancer research. The various areas that James L. Abbruzzese examines in his Cancer study include Immunohistochemistry, Carcinoma, Pathology, Progressive disease and Diabetes mellitus.
His scientific interests lie mostly in Internal medicine, Pancreatic cancer, Oncology, Cancer research and Cancer. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery. His study in Pancreatic cancer is interdisciplinary in nature, drawing from both Endocrinology, Pancreatic disease, Pancreas, Pathology and Genotype.
His Oncology research incorporates themes from Clinical trial, Phases of clinical research, Colorectal cancer, Capecitabine and Hepatocellular carcinoma. His Cancer research research includes elements of Carcinogenesis, Apoptosis, Protein kinase B and Metastasis. His Adenocarcinoma research focuses on Pancreaticoduodenectomy and how it connects with Neoadjuvant therapy.
His primary scientific interests are in Internal medicine, Pancreatic cancer, Oncology, Cancer research and Cancer. The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine. His work investigates the relationship between Pancreatic cancer and topics such as Pancreas that intersect with problems in Pancreatic Intraepithelial Neoplasia.
His Oncology research is multidisciplinary, incorporating elements of Chemotherapy, Hepatocellular carcinoma, Carcinoma, Biomarker and Survival analysis. His Cancer research research focuses on subjects like KRAS, which are linked to FGF21 and Adipose tissue. In Cancer, James L. Abbruzzese works on issues like Stage, which are connected to Lymph node.
James L. Abbruzzese spends much of his time researching Internal medicine, Oncology, Pancreatic cancer, Adenocarcinoma and Neoadjuvant therapy. His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine. The Oncology study combines topics in areas such as Hepatocellular carcinoma, Clinical endpoint, Carcinoma and Phases of clinical research.
James L. Abbruzzese interconnects Diabetes mellitus, Pathology, Gemcitabine, Surgical oncology and Radiation therapy in the investigation of issues within Pancreatic cancer. His Adenocarcinoma study integrates concerns from other disciplines, such as Surgery, Hypophosphatemia, Proto-oncogene tyrosine-protein kinase Src, Toxicity and Chemoradiotherapy. His research integrates issues of Pancreaticoduodenectomy and Pancreatic ductal adenocarcinoma in his study of Neoadjuvant therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Gideon Steinbach;Patrick M. Lynch;Robin K.S. Phillips;Marina H. Wallace.
The New England Journal of Medicine (2000)
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Navneet Dhillon;Bharat B. Aggarwal;Robert A. Newman;Robert A. Wolff.
Clinical Cancer Research (2008)
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty.
Journal of Clinical Oncology (2006)
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
J L Abbruzzese;R Grunewald;E A Weeks;D Gravel.
Journal of Clinical Oncology (1991)
The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells
Weixin Wang;James L. Abbruzzese;Douglas B. Evans;Lillie Larry.
Clinical Cancer Research (1999)
Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus
Manal M. Hassan;Lu Yu Hwang;Chiq J. Hatten;Mark Swaim.
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam;Vijaya Ramachandran;Keith Francis Fournier;Huamin Wang.
Cancer Research (2009)
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong.
Annals of Surgical Oncology (2006)
Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression
Hui Wen Lo;Sheng Chieh Hsu;Weiya Xia;Xinyu Cao.
Cancer Research (2007)
Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma
Christiane J. Bruns;Carmen C. Solorzano;Matthew T. Harbison;Shutaro Ozawa.
Cancer Research (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: